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Abstract We report the clinical course of three patients
with refractory juvenile dermatomyositis (JDM) who were
treated with tacrolimus. All three children had extensive skin
disease and severe muscle weakness and were corticosteroid
dependent. All three patients showed impressive improve-
ment of mainly the cutaneous lesions. Furthermore, overall
disease activity decreased, all children became more phys-
ically active, and corticosteroid treatment could be tapered.
However, none of the patients showed recovery of muscle
strength, which was most likely due to irreversible muscle
damage related to the long-standing myositis and/or high-
dose steroid treatment. Patients were followed up for 7 to
9 months after the introduction of tacrolimus. No adverse
effects were seen. These cases demonstrate that tacrolimus
has beneficial effects in children with refractory JDM,
especially in those with severe cutaneous manifestations.
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Introduction
Juvenile dermatomyositis (JDM) is the most common of the
paediatric inflammatory myopathies and is characterised by
proximal muscle weakness and rash. Corticosteroids are the
treatment of choice and have dramatically reduced morbidity
and mortality rates in the past decades [1]. Second-line agents
used to treat steroid-resistant disease or to induce steroid-
sparing effect in children include methotrexate (MTX),
intravenous immunoglobulins (IVIG), cyclophosphamide,
cyclosporine A, hydrochloroquine, mycophenolate mofetil
(MMF), rituximab and TNF-alpha antagonists [1]. Tacroli-
mus, an inhibitor of T-cell activation and proliferation, is one
of the new therapeutic options for JDM. Little is known
about its efficacy in this patient group.
Therefore, the goal of this case report is to describe our
experiences with tacrolimus in JDM patients. We present
three children with refractory JDM who showed positive
responses to oral tacrolimus.
Case reports
Case 1
A 6-year-old boywas diagnosed with JDM in December 2002.
Treatment was started with prednisolone 2 mg kg−1 day−1.
Substantial improvement of the severe muscle weakness was
not achieved until after additional treatment with MTX,
intravenous IVIG and rituximab in the 3 months following
admission. In the following years, relapses occurred despite
the medication and were treated with methylprednisolone
pulse therapy and IVIG. MTX was switched to MMF, and
hydrochloroquine was added. Muscle strength remained
stable in this period. Childhood Myositis Assessment Scale
(CMAS) score was between 36 and 40 (maximum score 52).
In September 2006, recurrence of severe myositis, accompa-
nied by dysphagia and vasculitis of the skin, led to prolonged
admission. Increase of the steroid dose and administration of
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rituximab did not improve his condition. The patient became
dependent on nightly oxygen, most likely due to respiratory
muscle weakness. Starting December 2006, monthly doses of
cyclophosphamide were given. Nevertheless, a relapse
occurred in April 2007, with predominant involvement of
the skin. In July/August 2007, the patient had developed
gastrointestinal manifestations of the dermatomyositis which
responded well to methylprednisolone pulse therapy. There
was diffuse erythema of the face and extremities, and the
serum muscle enzyme levels were elevated. Therefore, the
decision was made to introduce oral tacrolimus (target serum
level 10 μg/l, therapeutic range 5–15 μg/l). Three weeks after
starting tacrolimus, the patient had become more physically
active, the skin lesions started to resolve, and muscle enzyme
levels normalized. In the 7 months of follow-up, the patient
was able to walk greater distances, the cutaneous manifes-
tations showed impressive improvement with only very mild
erythema in the face, and the prednisolone was tapered down
to 0.1 mg kg−1 day−1 without any signs of exacerbation.
However, muscle weakness persisted (CMAS 36–38) and
was attributed to permanent muscle damage caused by the
myostis and steroid treatment. No adverse effects of the
tacrolimus were observed.
Case 2
A 6-year old girl was diagnosed with JDM in February 2007
after a 10-month history of progressive proximal muscle
weakness. During the prolonged admission that followed, the
patient was first treatedwithmethylprednisolone pulse therapy,
followed by oral prednisone 2 mg kg−1 day−1 and MTX. Due
to further loss of muscle strength, cyclophosphamide and
rituximab were administered. Still, she suffered from severe
myalgia, had a CMAS score of 4 and was bedridden. She
also had extensive skin lesions in the face, trunk and legs, and
the muscle enzymes remained elevated. Consequently,
tacrolimus was initiated in June 2007 while prednisolone
(0.8 mg kg−1 day−1) and MTX (20 mg m−2 week−1 s.c.) were
continued. Improvement started to show 2 to 3 weeks after
initiation of tacrolimus treatment. There was no myalgia, and
the patient was increasingly mobile, although there was still
severe muscle weakness with a CMAS score of 10 and
muscle contractures in the lower extremities that severely
impaired further ambulation. Skin involvement was signifi-
cantly reduced, and the serum muscle enzyme levels
decreased gradually. In the following 4 weeks, she partici-
pated more in daily activities, and the skin lesion continued to
improve. No side effects of the tacrolimus were seen in the
9 months of follow-up. Because of the severity of the disease
activity, after reaching remission status with tacrolimus,
autologous bone marrow transplantation was performed.
Case 3
A 4-year-old girl was diagnosed as having JDM in March
2003. She initially responded to treatment with prednisolone
2 mg kg−1 day−1 and IVIG. However, she relapsed during
tapering of the prednisolone. Steroid pulse therapy, MTX
and IVIG were needed to control disease activity. In the
second half of 2004, increased muscle weakness, vasculitis
of the skin and extensive calcifications that first started in
the lower extremities and later involved the upper extrem-
ities were observed. A new course of IVIG did not improve
the skin involvement. Subsequently, rituximab was given to
stabilise disease activity and taper down the prednisolone.
However, tapering of the steroids again led to increased
myositis and skin activity. As the patient was becoming
increasingly impaired in daily activities despite additional
treatment with MMF (1 g/day) and hydrochloroquine,
tacrolimus was introduced in July 2007. At that time,
muscle enzyme levels were within normal range, and
CMAS score was 28. Two weeks later, improvement of
the skin disease was observed. In the following 8 months,
most of the cutaneous lesions disappeared, the patient
became more energetic and was even able to run again. The
prednisolone dose was reduced to 0.15 mg kg−1 day−1. No
side effects of the tacrolimus were observed.
Discussion
Tacrolimus is a calcineurin inhibitor that suppresses the IL-2-
dependant T-cell activation [2]. It is widely used in transplant
medicine and has been shown to be effective in several
autoimmune diseases including rheumatoid arthritis, systemic
lupus erythematosus and inflammatory bowel disease [3–5].
Beneficial effects of tacrolimus have also been demonstrated
in adult polymyositis and dermatomyositis [6–10]. Little is
known about the efficacy of systemic tacrolimus in juvenile
dermatomyositis. There have been three case reports on this
topic [11–13]. Yamada et al. reported a 13-year-old girl with
steroid-dependant JDM who was previously treated with
MTX, azathioprine, IVIG and cyclosporine A [11] and
showed significant improvement only after introduction of
tacrolimus. Three other children were described by Modesto
et al. [12]. After 1 year of tacrolimus treatment, muscle
strength normalised in all three patients, skin abnormalities
resolved completely in two children and improved substan-
tially in the third and steroid treatment could be discontinued
in two children, while the dose was tapered in the third.
Finally, in a report of six children, who were given
tacrolimus for 1 year, Martin Nalda et al. showed significant
improvement of both muscle strength and skin disease [13].
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The three case descriptions presented in the current report
also suggest beneficial effects of tacrolimus treatment. All
three patients had extensive vasculitis of the skin and severe
muscle weakness. The skin lesions improved greatly in all
patients but did not resolve completely during the follow-up
period of 7 to 9 months. The myositis also seemed to respond
to the tacrolimus, as muscle enzyme levels normalised in
patients 1 and 2, and the myalgia disappeared in patient 2.
However, we did not see any improvement of muscle strength.
This could be explained by the prolonged disease course and/
or high-dose corticosteroid treatment that might have caused
irreversible muscle damage or the relatively short follow-up
period after controlling the disease with tacrolimus, which
may not have allowed the muscles to sufficiently restore their
strength. It should be noted that, despite the persisting muscle
weakness, all patients indicated feeling more energetic and
had become more physically active during treatment with
tacrolimus. Furthermore, it was possible to effectively reduce
the steroid dose in patients 1 (from 0.6 to 0.1 mg kg−1 day−1)
and 3 (from 0.3 to 0.15 mg kg−1 day−1). This steroid-sparing
effect could be explained by the finding that tacrolimus
inhibits steroid exporters and increases the hormone-binding
function of the glucocorticosteroid receptor [14].
The most common side effects of tacrolimus are
concentration-dependant and include gastrointestinal symp-
toms, hypertension, nefrotoxicity, neurotoxicity, disturban-
ces in glucose metabolism, hyperkalaemia, tremor,
headache and sleeping disorders [2]. No adverse effects
were observed in our patients. This is in line with findings
from previous case reports that showed tacrolimus to be
safe after a follow-up period of 1 to 2 years [11–13].
In conclusion, this case report indicates that tacrolimus
can substantially improve the cutaneous manifestations of
JDM. When administered in an early phase, muscle
weakness may improve as well. Therefore, tacrolimus
should be considered in JDM cases that are refractory to
other immunosuppressive medication.
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